D-0170-2020 Class II

Recalled by Dr. Reddy's Laboratories, Inc. — Princeton, NJ

FDA drug recall D-0170-2020 was initiated by Dr. Reddy's Laboratories, Inc. on Oct 1, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product.

Recall details

Product Type
Drugs
Report Date
Nov 13, 2019
Initiation Date
Oct 1, 2019
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 0363-0010-34), b.) 65 count bottles (NDC 0363-0010-61) , c.) 95 count bottles (NDC 0363-0010-62), d.) 200 count bottles (NDC 0363-0010-01) (Walgreens) OTC

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Product was distributed to major distributors throughout the United States who may have further distributed the product.

Code information

Batch Numbers: All lots within expiry.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0170-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0170-2020. Report a data issue: hello@regdatalab.com.